Special Protocol Assessment (SPA) agreement with the U.S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic neuritis (ON) FDA Breakthrough Therapy and EMA PRIME designations in ON underscore the significant unmet need and therapeutic potential of Privosegtor as a neuroprotective candidateZUG, Switzerland, May 7 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) regarding PIONEER-1, the first registrational trial within the PIONEER Program evaluating Privosegtor for the treatment of...

Establishes domestic platform in advanced graphite, addressing a multi-billion-dollar end market underpinned by U.S. supply-chain reshoring and next-generation nuclear deployment TOMI Environmental Solutions, Inc. and Carbonium Core, Inc. to Present at Wall Street Reporter’s Next Super Stocks Livestream May 7, 2026, at 1:00pm ET FREDERICK, Md., May 07, 2026 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc.® (Nasdaq: TOMZ) (“TOMI” or the “Company”) today is providing clarification regarding its previously announced non-binding letter of intent (the “LOI”) for a merger transaction to acquire 100% of the outstanding equity of Carbonium Core, Inc. (“Carbonium Core”), a U.S.-based developer of nuclear-grade graphite for advanced reactor technologies (the “Proposed Transaction”). Transaction Summary: TOMI provide all-stock consideration...

LONDON, May 07, 2026 (GLOBE NEWSWIRE) — StepStone Group (Nasdaq: STEP), a leading global private markets investment firm, today announced it has joined LSEG’s Digital Markets Infrastructure (DMI) platform. Fully integrated within LSEG Workspace, the DMI platform streamlines professional investor access to private funds and utilises distributed ledger technology to support private fund distribution, helping to reduce structural barriers to private markets access for investors. StepStone is among the first private markets managers launching on the DMI platform, with StepStone’s evergreen strategies across private equity, private debt and infrastructure available. This collaboration builds on StepStone’s existing relationship with LSEG. In October 2025, the two launched the FTSE StepStone Global Private Market Indices, which offer...

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577Date Total number of shares representing the share capital Total number of voting rightsApril, 30 2026 8 390 660 Gross total of voting rights : 12 707 056Net total* of voting rights : 12 698 020Net total* = total number of voting rights attached to the total number of shares net of shares with no voting rights. VIRBAC: Shaping the future of animal healthNYSE Euronext – Compartiment A / Code ISIN: FR0000031577 / MNEMO: VIRPCorporate Finance: tel. 33 4 92 08 71 32 / Email: finances@virbac.comWebsite:...

Once fully rolled out, the landmark modernization program will cover the bank’s branch network and more than 40 million accounts GRAND-LANCY, Switzerland and COPENHAGEN, Denmark, May 07, 2026 (GLOBE NEWSWIRE) — Temenos (SIX: TEMN), a global leader in banking technology, today announced that Habib Bank Limited (HBL), a leading financial institution in Pakistan, has successfully gone live with Temenos Core Banking in one of the region’s most ambitious modernization programs. The initial go-live supports Conventional and Islamic Banking and includes a first phase migration of customer accounts from 200 branches in Pakistan to the Temenos platform. The milestone is a major step in HBL’s strategy to deliver agility, resilience, and scalability in its operations. Once fully rolled out, this landmark program will cover the Bank’s branch...

New Temenos AI agents, copilots and conversational studio embed intelligence into the trusted core of banking GRAND-LANCY, Switzerland and COPENHAGEN, Denmark, May 07, 2026 (GLOBE NEWSWIRE) — Temenos (SIX: TEMN), a global leader in banking technology, today announced new AI-powered product capabilities launching at Temenos Community Forum (TCF) 2026. The new releases include Temenos AI Agents, Copilots and Conversational Studio embedded across Temenos’ Core and Digital Banking products, as well as its Financial Crime Mitigation (FCM) solution. These launches demonstrate Temenos’ continued execution against the product pillar of its AI strategy, which focuses on embedding intelligence into the trusted platform banks rely on to run their most critical operations. The new AI capabilities unveiled at TCF 2026 include:Conversational...

PRESS RELEASEParis, 07 May, 2026 Information on the total number of voting rightsand shares forming the share capital(Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of the French Financial Markets Authority)Date Issued capital Par value Total number of shares Total number of voting rightsTheoretical* Exercisable**  April 30, 2026   € 245,607,624 € 1 245,607,624 276,338,794 273,674,945*In accordance with Article 223-11 of the General Regulation of the French Financial Markets Authority, the total number of theoretical voting rights is calculated on the basis of all shares to which voting rights are attached, including shares deprived of voting rights.**The total number of exercisable voting rights is calculated without taking into account shares deprived of voting rights.About...

As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla., May 07, 2026 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that the Company and its licensor SERB S.A. (“SERB”) have entered into a Settlement Agreement (“Agreement”) with Hetero Labs Ltd., Hetero USA, Grace Consulting Services, Inc., and Annora Pharma Private Limited (collectively, Hetero). This Agreement resolves the patent litigation brought by Catalyst and SERB in response to Hetero’s Abbreviated...